{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:50:46Z","timestamp":1778827846505,"version":"3.51.4"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.det.2020.05.012","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T08:34:40Z","timestamp":1597134880000},"page":"523-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adverse Drug Events in the Oral Cavity"],"prefix":"10.1016","volume":"38","author":[{"given":"Anna","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook-Bin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9237","key":"10.1016\/j.det.2020.05.012_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-016-0153-9","article-title":"A\u00a0guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the World Workshop on Oral Medicine VI","volume":"17","author":"Wolff","year":"2017","journal-title":"Drugs R D"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib4","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib5","first-page":"89","article-title":"Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation","volume":"49","author":"Ismail","year":"2007","journal-title":"J\u00a0Oral Sci"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1440-0960.1995.tb00953.x","article-title":"Mechanisms of drug eruptions: part I","volume":"36","author":"Breathnach","year":"1995","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.det.2020.05.012_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fendo.2017.00310","article-title":"The association of thyroid disease and oral lichen planus: a literature review and meta-analysis","volume":"8","author":"Li","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0738-081X(00)00142-5","article-title":"Oral lichen planus","volume":"18","author":"Sugerman","year":"2000","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2010.01322.x","article-title":"Lichen planus and lichenoid reactions of the oral mucosa","volume":"23","author":"Schlosser","year":"2010","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib10","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-0960.2006.00225.x","article-title":"Pravastatin-induced lichenoid drug eruption","volume":"47","author":"Pua","year":"2006","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ijd.13852","article-title":"Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients","volume":"57","author":"Vinay","year":"2018","journal-title":"Int J Dermatol"},{"issue":"16","key":"10.1016\/j.det.2020.05.012_bib14","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-05-0354","article-title":"Letrozole in\u00a0the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen","volume":"11","author":"Mann","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/j.gastro.2007.01.014","article-title":"Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab","volume":"132","author":"Moss","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.crohns.2011.01.003","article-title":"Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease","volume":"5","author":"Mocciaro","year":"2011","journal-title":"J\u00a0Crohns Colitis"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archderm.143.2.233","article-title":"The yin and yang of TNF-{alpha} inhibition","volume":"143","author":"Fiorentino","year":"2007","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13555-012-0003-9","article-title":"GA101 (a novel anti-CD20 monoclonal antibody)-induced lichenoid eruption","volume":"2","author":"Bakkour","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib20","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jaad.2012.08.019","article-title":"Oral mucosal fixed drug eruption: characteristics and differential diagnosis","volume":"69","author":"Ozkaya","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1365-2133.2002.49886.x","article-title":"Multiple fixed drug eruptions due to cetirizine","volume":"147","author":"Inamadar","year":"2002","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2020.05.012_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1365-4632.2004.02454.x","article-title":"Fixed drug eruption: a novel side-effect of levocetirizine","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/0378-6323.27767","article-title":"Oral fixed drug eruption due to fluconazole","volume":"72","author":"Mahendra","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5 Pt 2","key":"10.1016\/j.det.2020.05.012_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0190-9622(00)90262-7","article-title":"Fixed drug eruption due to fluconazole","volume":"42","author":"Heikkila","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.0105-1873.2005.0650h.x","article-title":"Fixed drug eruption on the tongue due to clarithromycin","volume":"53","author":"Alonso","year":"2005","journal-title":"Contact Dermatitis"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1468-3083.2009.03124.x","article-title":"Oral fixed drug eruption caused by gabapentin","volume":"23","author":"Gupta","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib27","first-page":"E1","article-title":"Oral fixed drug eruption due to tinidazole","volume":"98","author":"Singh","year":"2016","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1203475418756376","article-title":"Drug eruption to rosuvastatin with recurrence on simvastatin: a case report","volume":"22","author":"Wong","year":"2018","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib29","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.18295\/squmj.2018.18.03.025","article-title":"A\u00a0probable case of mucosal fixed drug eruption following treatment with silodosin","volume":"18","author":"Klimi","year":"2018","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1046\/j.1365-2133.2000.03898.x","article-title":"Role of drug exposure in aphthous ulcers: a case-control study","volume":"143","author":"Boulinguez","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1601-0825.2004.01024.x","article-title":"Adverse oral reactions associated with the COX-2 inhibitor rofecoxib","volume":"10","author":"Bagan","year":"2004","journal-title":"Oral Dis"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib32","first-page":"197","article-title":"Aphtous ulcers of the mouth associated with losartan","volume":"50","author":"Goffin","year":"1998","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.det.2020.05.012_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A\u00a0review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"de Oliveira","year":"2011","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/SPC.0b013e328335fb76","article-title":"Regimen-related gastrointestinal toxicities in cancer patients","volume":"4","author":"Sonis","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib36","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.oooo.2014.08.018","article-title":"Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy","volume":"118","author":"Philipone","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib37","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1345\/aph.1K592","article-title":"Sunitinib adverse event: oral bullous and lichenoid mucositis","volume":"43","author":"Mignogna","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"4\u20135","key":"10.1016\/j.det.2020.05.012_bib38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2230.1996.tb00033.x","article-title":"Bullous pemphigoid and penicillamine","volume":"21","author":"Weller","year":"1996","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000245685","article-title":"Diclofenac: a new trigger of pemphigus vulgaris?","volume":"195","author":"Matz","year":"1997","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin Dermatol"},{"issue":"9","key":"10.1016\/j.det.2020.05.012_bib42","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib44","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.oooo.2012.08.001","article-title":"Erythema multiforme major following treatment with infliximab","volume":"115","author":"Edwards","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"35","key":"10.1016\/j.det.2020.05.012_bib45","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.3748\/wjg.15.4449","article-title":"Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease","volume":"15","author":"Salama","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/aam.aam_19_17","article-title":"Drug-induced oral erythema multiforme: a diagnostic challenge","volume":"17","author":"Taqi","year":"2018","journal-title":"Ann Afr Med"},{"issue":"8","key":"10.1016\/j.det.2020.05.012_bib47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"issue":"16","key":"10.1016\/j.det.2020.05.012_bib48","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.det.2020.05.012_bib49","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.det.2020.05.012_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"10.1016\/j.det.2020.05.012_bib51","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B\u22175801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis","volume":"20","author":"Yu","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40291-018-0330-3","article-title":"Drug-induced skin adverse reactions: the role of pharmacogenomics in their prevention","volume":"22","author":"Gerogianni","year":"2018","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tripleo.2008.07.022","article-title":"Pigmentation of the hard palate","volume":"107","author":"Lerman","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib54","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.oooo.2017.10.006","article-title":"Drug-associated hyperpigmentation of the oral mucosa: report of four cases","volume":"125","author":"Tosios","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.det.2020.05.012_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/154411130401500405","article-title":"Adverse drug reactions in the orofacial region","volume":"15","author":"Scully","year":"2004","journal-title":"Crit Rev Oral Biol Med"},{"issue":"8","key":"10.1016\/j.det.2020.05.012_bib57","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/qjmed\/hcq131","article-title":"Amiodarone-induced skin hyperpigmentation","volume":"104","author":"Stahli","year":"2011","journal-title":"QJM"},{"issue":"8","key":"10.1016\/j.det.2020.05.012_bib58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/ijd.13085","article-title":"Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia","volume":"55","author":"Molina-Ruiz","year":"2016","journal-title":"Int J Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.det.2020.05.012_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-051X.1996.tb02072.x","article-title":"The pathogenesis of drug-induced gingival overgrowth","volume":"23","author":"Seymour","year":"1996","journal-title":"J\u00a0Clin Periodontol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib60","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/odi.12264","article-title":"Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis","volume":"21","author":"Brown","year":"2015","journal-title":"Oral Dis"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib61","first-page":"1127","article-title":"Non-gingival soft tissue growths after allogeneic marrow transplantation","volume":"17","author":"Woo","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.det.2020.05.012_bib62","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1600-0714.2007.00557.x","article-title":"Calcineurin inhibitor-associated oral inflammatory polyps after transplantation","volume":"36","author":"Al-Mohaya","year":"2007","journal-title":"J\u00a0Oral Pathol Med"},{"issue":"11","key":"10.1016\/j.det.2020.05.012_bib63","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1600-051X.2006.00990.x","article-title":"Relationship between IL-1A polymorphisms and gingival overgrowth in renal transplant recipients receiving cyclosporin A","volume":"33","author":"Bostanci","year":"2006","journal-title":"J\u00a0Clin Periodontol"},{"issue":"20","key":"10.1016\/j.det.2020.05.012_bib64","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1200\/JCO.2010.32.4095","article-title":"Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study","volume":"29","author":"Le","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ijos.2013.93","article-title":"Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study","volume":"6","author":"Lauritano","year":"2014","journal-title":"Int J Oral Sci"},{"issue":"7","key":"10.1016\/j.det.2020.05.012_bib66","doi-asserted-by":"crossref","first-page":"867","DOI":"10.14219\/jada.archive.2010.0285","article-title":"Generalized white appearance of the oral mucosa. Hyperkeratosis secondary to palifermin","volume":"141","author":"Lerman","year":"2010","journal-title":"J\u00a0Am Dent Assoc"},{"issue":"25","key":"10.1016\/j.det.2020.05.012_bib67","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1056\/NEJMoa040125","article-title":"Palifermin for oral mucositis after intensive therapy for hematologic cancers","volume":"351","author":"Spielberger","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2020.05.012_bib68","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/exd.12249","article-title":"No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients","volume":"22","author":"Ganzenmueller","year":"2013","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.05.012_bib69","first-page":"138","article-title":"Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and acute lymphoblastic leukemia","volume":"3","author":"Dorchin","year":"2013","journal-title":"Iran J Ped Hematol Oncol"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib70","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/11593120-000000000-00000","article-title":"Drug-induced taste and smell alterations: a case\/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting","volume":"34","author":"Tuccori","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.det.2020.05.012_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fphar.2013.00156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","volume":"4","author":"Han","year":"2013","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib72","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.det.2020.05.012_bib73","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.oraloncology.2015.09.003","article-title":"Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors","volume":"51","author":"Yuan","year":"2015","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib74","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.det.2020.05.012_bib75","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib77","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib78","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications","volume":"113","author":"Nicolatou-Galitis","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"24","key":"10.1016\/j.det.2020.05.012_bib79","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.det.2020.05.012_bib80","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bjoms.2016.11.315","article-title":"Medication-related osteonecrosis of the jaw associated with aflibercept","volume":"55","author":"Zarringhalam","year":"2017","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib83","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.det.2020.05.012_bib84","first-page":"E155","article-title":"Head and neck lesions in the immunocompromised host","volume":"14","author":"Marsot-Dupuch","year":"2004","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib85","first-page":"1389","article-title":"Orofacial viral infections in the immunocompromised host","volume":"7","author":"Samonis","year":"2000","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib86","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1155\/2009\/180840","article-title":"Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort","volume":"23","author":"Teshima","year":"2009","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib87","first-page":"269","article-title":"Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"22","author":"Deepak","year":"2013","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib88","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/ar3058","article-title":"74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis","volume":"12","author":"Delabaye","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"19","key":"10.1016\/j.det.2020.05.012_bib89","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib90","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","article-title":"Infectious complications associated with monoclonal antibodies and related small molecules","volume":"22","author":"Salvana","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijporl.2011.07.016","article-title":"Antihypertensive drug-induced angioedema causing upper airway obstruction in children","volume":"76","author":"Hom","year":"2012","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib92","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjoto.2010.11.014","article-title":"Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis","volume":"32","author":"Shino","year":"2011","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"10.1016\/j.det.2020.05.012_bib93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjopharm.2006.12.002","article-title":"Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature","volume":"4","author":"Ruscin","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.det.2020.05.012_bib94","first-page":"149","article-title":"Simvastatin: a risk factor for angioedema?","volume":"29","author":"Nisly","year":"2013","journal-title":"J\u00a0Pharm Technol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib95","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.semdp.2012.08.005","article-title":"Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders","volume":"30","author":"Bagg","year":"2013","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1016\/j.det.2020.05.012_bib96","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib98","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1365-2133.2003.05735.x","article-title":"Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin","volume":"149","author":"Niwa","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.05.012_bib99","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.tripleo.2010.02.030","article-title":"Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus","volume":"110","author":"Mattsson","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.det.2020.05.012_bib100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2407-6-7","article-title":"The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report","volume":"6","author":"Becker","year":"2006","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.det.2020.05.012_bib101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12165","article-title":"Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients","volume":"26","author":"Wimmer","year":"2013","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.det.2020.05.012_bib102","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaad.2006.01.054","article-title":"The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force","volume":"54","author":"Berger","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.05.012_bib103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2133.2011.10363.x","article-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors","volume":"165","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib104","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bjd.13610","article-title":"Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors","volume":"172","author":"Vigarios","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jdv.13105","article-title":"Vemurafenib mucosal side-effect","volume":"30","author":"Pileri","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2020.05.012_bib106","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.det.2020.05.012_bib107","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1345\/aph.1P309","article-title":"Association between cancer and immunosuppressive therapy: analysis of selected studies in pemphigus and pemphigoid","volume":"44","author":"Mabrouk","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.det.2020.05.012_bib108","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.det.2020.05.012_bib109","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.det.2020.05.012_bib110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bmt.2011.77","article-title":"Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes","volume":"46","author":"Mawardi","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520300462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520300462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:44:58Z","timestamp":1760006698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863520300462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0733863520300462"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2020.05.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Drug Events in the Oral Cavity","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2020.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}